Hiba Therapeutics
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Hiba Therapeutics is a Cambridge, MA-based clinical-stage immunotherapy company developing TROIKA, a first-in-class AND-gated antibody-peptide conjugate (APC) platform for solid tumors. Current checkpoint inhibitors activate fewer than 10% of tumor-infiltrating lymphocytes - the exhausted, tumor-antigen-specific subset. TROIKA redirects the other 90%: non-exhausted, bystander T cells that retain full cytotoxic potential but are ignored by existing therapies.
The platform's AND-logic gate requires simultaneous tumor-surface binding and T cell engagement, restricting immune activation exclusively to the tumor microenvironment. This eliminates the on-target and off-target toxicity that limits TCEs, CAR-T, and checkpoint combinations. Our lead asset, HIB 117, has demonstrated greater than 80% objective response rate in syngeneic lung cancer models with no detectable toxicity across six organ systems. DC nomination is on track for Q4 2026, with an IND submission targeted for Q3 2028.
Company HQ City:
Cambridge, MA
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2026
Lead Product in Development:
HIB 117
CEO
Shariq Usmani
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Q3 2026
What is your next catalyst (value inflection) update?
Development Candidate (DC) Nomination of HIB 117 - the formal designation of our lead TROIKA molecule as ready to advance into IND-enabling studies. This milestone integrates completed lead optimization, confirmed in vivo efficacy and selectivity data, and a preliminary in vitro safety package into a DC dossier. It represents the transition from discovery to development and is the standard trigger for initiating Series A fundraising conversations in the biotech industry.
Secondary catalysts in close succession: PCT patent filing (Q3 2026) and initiation of GLP toxicology studies (Q1 2027), which together de-risk the asset for partnership and licensing discussions.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}